German university hospital strong in autoimmune disease, bone biology, cancer research, and increasingly in digital health and AI-driven clinical imaging.
Universitätsklinikum Erlangen is a major German university hospital that combines clinical care with translational biomedical research, particularly in autoimmune and inflammatory diseases, bone biology, cancer, and rare diseases. Their research spans from molecular mechanisms (epigenetics, organoids, microbiome) through advanced imaging and digital health tools to clinical trials and personalized treatment strategies. They bring deep clinical cohort access and patient data infrastructure to EU consortia, bridging the gap between laboratory discoveries and bedside application across immunology, oncology, and musculoskeletal medicine.
Core focus spanning RTCure (rheumatoid arthritis tolerance), BARRIER BREAK (skin-to-joint inflammation), H I C I (CNS autoimmune inflammation), NeutroCure (neutrophil-driven autoimmunity), HIPPOCRATES (psoriatic arthritis), and REDOXIT (ROS in chronic disease).
Coordinator of both 4-D nanoSCOPE (bone microstructure imaging via X-ray microscopy) and ODE (osteocyte death mechanisms), plus involvement in osteoporosis and arthritis research.
Spans ONCOBIOME (gut microbiome in cancer), RESCUER (combinatorial breast cancer therapies), PRECODE (pancreatic cancer organoids network), and HYPERBOOST (hyperthermia treatment planning).
MOBILISE-D (digital mobility assessment), SCREEN4CARE (newborn screening with digital platforms and machine-learning), and IMMERSE (digital mobile mental health).
SCREEN4CARE (rare disease diagnosis via newborn genetic screening), ID-EPTRI (paediatric translational research infrastructure), and Degradation_ID (FBXO11-related intellectual disability).
4-D nanoSCOPE applies 4D X-ray microscopy with deep learning for bone imaging; EUPHORIA develops ultrasound and photoacoustic recognition of intestinal abnormalities.
In their early H2020 period (2015–2018), Erlangen focused on foundational disease mechanisms — diabetic kidney disease biomarkers (BEAt-DKD), rheumatoid arthritis tolerance (RTCure), tinnitus research (TIN-ACT), and AIDS vaccine development (EAVI2020). From 2019 onward, their portfolio shifted markedly toward digital health tools (digital mobility assessment, machine-learning phenotypic checkers, digital mental health), advanced imaging with computational methods (4D X-ray microscopy, deep learning for bone structure), and translational cancer approaches using organoids and combinatorial therapies. The trend shows a hospital moving from classical clinical research participation toward computationally enriched, imaging-intensive translational medicine.
Erlangen is increasingly integrating digital tools, deep learning, and advanced imaging into clinical research — expect future projects at the intersection of AI-driven diagnostics and inflammatory/musculoskeletal medicine.
Erlangen operates as both a project leader and a valued consortium partner, coordinating 7 of 27 projects (26%) — a strong rate for a clinical institution. Their 300 unique partners across 32 countries indicate a wide, non-exclusive network typical of a well-connected university hospital that different consortia recruit for clinical expertise and patient cohort access. They participate comfortably in both large IMI-scale health consortia (BEAt-DKD, PREFER, SCREEN4CARE) and focused ERC-funded teams, making them a flexible collaboration partner.
With 300 unique consortium partners across 32 countries, Erlangen maintains one of the broader collaboration networks among German university hospitals in H2020, with strong ties across Western and Northern Europe and participation in both large public-private partnerships and smaller investigator-driven projects.
Erlangen stands out for combining deep clinical immunology and inflammatory disease expertise with growing computational and imaging capabilities — few university hospitals bridge autoimmune disease research, bone biology, and AI-driven diagnostics under one roof. Their 3 ERC Starting Grants (SOS, 4-D nanoSCOPE, ODE) signal exceptional individual research talent, while their participation in large IMI projects (BEAt-DKD, PREFER, SCREEN4CARE) demonstrates capacity for industry-scale clinical data work. For consortium builders, they offer both the patient cohort access of a large university hospital and the methodological innovation of a research-intensive lab.
